Ann: Further update on PAT-DX1 GMP manufacturing run, page-37

PAB is a new bio penny stock i have just invested in. My other bio stock i bought this month went from .006 to .013 now .
Over a 100 percent rise so this stock has the same potential.This therapeutic antibody (ASXAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers.
If they are successful this stock will rise so fast doubters will be left behind.
PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens. Patrys believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells.